Status:
COMPLETED
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus
Lead Sponsor:
Merz Pharmaceuticals GmbH
Conditions:
Subjective Tinnitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
Eligibility Criteria
Inclusion
- Main
- Patients aged between 18 and 75 years with a clinical diagnosis of first onset, persistent (i.e., tinnitus should never be absent for \> 24 hours in a row), subjective, uni- or bilateral subacute tinnitus
- Main
Exclusion
- Clinical diagnosis of intermittent or pulsatile tinnitus
- Patients who have tinnitus as a concomitant symptom of an otological/neurological disease (such as otitis media, Menière's disease, otosclerosis, etc)
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
455 Patients enrolled
Trial Details
Trial ID
NCT00955799
Start Date
September 1 2009
End Date
June 1 2011
Last Update
November 28 2012
Active Locations (76)
Enter a location and click search to find clinical trials sorted by distance.
1
Horizon Clinical Research Associates PLLC
Gilbert, Arizona, United States, 85295
2
Phoenix Clinical
Phoenix, Arizona, United States, 85015
3
Paradigm Clinical Research
Tucson, Arizona, United States, 85705
4
Providence Clinical Research
Burbank, California, United States, 91505